NASDAQ:VYGR - Voyager Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$19.78 0.00 (0.00 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$19.78
Today's Range$19.70 - $20.18
52-Week Range$8.10 - $31.91
Volume142,685 shs
Average Volume414,046 shs
Market Capitalization$639.31 million
P/E Ratio-7.49
Dividend YieldN/A
Beta2.98

About Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics logoVoyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopathies, including Alzheimer's disease, PSP, and FTD; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with AbbVie Inc.; Sanofi Genzyme; and the University of Massachusetts. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VYGR
CUSIPN/A
Phone857-259-5340

Debt

Debt-to-Equity RatioN/A
Current Ratio7.13
Quick Ratio7.13

Price-To-Earnings

Trailing P/E Ratio-7.49
Forward P/E Ratio-7.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.14 million
Price / Sales63.05
Cash FlowN/A
Price / CashN/A
Book Value$3.04 per share
Price / Book6.51

Profitability

EPS (Most Recent Fiscal Year)($2.64)
Net Income$-70,690,000.00
Net Margins-768.99%
Return on Equity-69.92%
Return on Assets-41.13%

Miscellaneous

Employees88
Outstanding Shares32,320,000

Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics (NASDAQ:VYGR) posted its quarterly earnings data on Thursday, May, 10th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.52. The company earned $0.94 million during the quarter, compared to the consensus estimate of $4 million. Voyager Therapeutics had a negative net margin of 768.99% and a negative return on equity of 69.92%. View Voyager Therapeutics' Earnings History.

What price target have analysts set for VYGR?

11 brokerages have issued 12-month price targets for Voyager Therapeutics' shares. Their forecasts range from $12.00 to $40.00. On average, they expect Voyager Therapeutics' stock price to reach $30.10 in the next year. View Analyst Ratings for Voyager Therapeutics.

What are Wall Street analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:
  • 1. BTIG Research analysts commented, "Before mkt open on Thursday, Voyager released their 1Q18 financial results and update. Management reconfirmed that the first patient in the Phase 2-3 Parkinson’s (PD) studies could be dosed during mid-2018, and further confirmed that posterior delivery will be the preferred approach. The decision to use posterior delivery was based upon improved safety, surgical time, and coverage of the putamen – with first data from the posterior study being presented later in 2Q18. The posterior study dataset will focus on patients with 6-months of follow-up, which will be a small group of patients, as the 8 th patient in the posterior study was recently dosed. We reiterate our Buy rating and $32 PT as we remain positive on the PD effort." (5/13/2018)
  • 2. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/20/2018)
  • 3. Canaccord Genuity analysts commented, "We note, however, that the IND acceptance is a key step that allows VYGR to start its pivotal Phase 2-3 trial program per plan in 2Q18. VYGR has several potential catalysts coming up over the course of 2018 (see Table 1 on page 2 for details). Specifically, in our view, longer-term Phase 1b data (readouts over 2018) could favorably support the continued development of VY-AADC in advanced PD, and we are reiterating our BUY ahead of the availability of these data." (1/23/2018)

Who are some of Voyager Therapeutics' key competitors?

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the folowing people:
  • Dr. Steven M. Paul, CEO, Pres & Director (Age 67)
  • Dr. Dinah Sah Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Robert G. Pietrusko Pharm. D., Sr. VP of Regulatory Affairs & Quality Assurance (Age 70)
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder

Has Voyager Therapeutics been receiving favorable news coverage?

Media coverage about VYGR stock has trended somewhat positive this week, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Voyager Therapeutics earned a news impact score of 0.10 on Accern's scale. They also assigned media coverage about the company an impact score of 46.73 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BB Biotech AG (6.17%), BlackRock Inc. (4.45%), Farallon Capital Management LLC (2.75%), Millennium Management LLC (1.91%), Wells Fargo & Company MN (1.21%) and Northern Trust Corp (0.62%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina, Dinah PhD Sah and Jane Henderson. View Institutional Ownership Trends for Voyager Therapeutics.

Which institutional investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including Altrinsic Global Advisors LLC, Wells Fargo & Company MN, Dimensional Fund Advisors LP, Citadel Advisors LLC and Birchview Capital LP. Company insiders that have sold Voyager Therapeutics company stock in the last year include Bernard Ravina, Dinah PhD Sah and Jane Henderson. View Insider Buying and Selling for Voyager Therapeutics.

Which institutional investors are buying Voyager Therapeutics stock?

VYGR stock was acquired by a variety of institutional investors in the last quarter, including BB Biotech AG, Millennium Management LLC, Farallon Capital Management LLC, BlackRock Inc., JPMorgan Chase & Co., Fiduciary Trust Co., UBS Group AG and A.R.T. Advisors LLC. View Insider Buying and Selling for Voyager Therapeutics.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $19.78.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $639.31 million and generates $10.14 million in revenue each year. The company earns $-70,690,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Voyager Therapeutics employs 88 workers across the globe.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]


MarketBeat Community Rating for Voyager Therapeutics (VYGR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  340
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Voyager Therapeutics (NASDAQ:VYGR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Voyager Therapeutics in the last 12 months. Their average twelve-month price target is $30.10, suggesting that the stock has a possible upside of 52.17%. The high price target for VYGR is $40.00 and the low price target for VYGR is $12.00. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.912.822.922.90
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.10$30.10$28.2727$26.1250
Price Target Upside: 52.17% upside64.03% upside19.50% upside101.74% upside

Voyager Therapeutics (NASDAQ:VYGR) Consensus Price Target History

Price Target History for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2018BTIG ResearchReiterated RatingBuyHighView Rating Details
5/11/2018WedbushUpgradeNeutral ➝ OutperformHighView Rating Details
5/10/2018Canaccord GenuitySet Price TargetBuy$35.00HighView Rating Details
3/12/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Buy$40.00HighView Rating Details
2/21/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$36.00 ➝ $39.00HighView Rating Details
10/31/2017Chardan CapitalReiterated RatingHold$17.00N/AView Rating Details
10/31/2017CowenReiterated RatingBuyN/AView Rating Details
10/30/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$31.00N/AView Rating Details
10/23/2017Stifel NicolausReiterated RatingBuy ➝ Buy$20.00 ➝ $31.00N/AView Rating Details
10/12/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$35.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$12.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy ➝ Buy$31.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Voyager Therapeutics (NASDAQ:VYGR) Earnings History and Estimates Chart

Earnings by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) Earnings Estimates

2018 EPS Consensus Estimate: ($2.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.68)($0.68)($0.68)
Q2 20181($0.70)($0.70)($0.70)
Q3 20181($0.71)($0.71)($0.71)
Q4 20181($0.73)($0.73)($0.73)

Voyager Therapeutics (NASDAQ VYGR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1($0.11)($0.6270)$4.00 million$0.94 millionViewN/AView Earnings Details
3/14/2018Q4 2017($0.72)($0.40)$5.81 million$6.35 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.72)($0.89)$1.26 million$1.15 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.62)($0.73)$3.27 million$1.18 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.54)($0.65)$3.70 million$1.46 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.46)($0.57)$4.15 million$2.36 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.41)($0.35)$4.36 million$3.31 millionViewN/AView Earnings Details
8/11/2016Q2($0.34)($0.37)$4.79 million$3.72 millionViewListenView Earnings Details
5/12/2016Q1($0.38)$0.29$5.00 million$4.83 millionViewListenView Earnings Details
3/17/2016Q4($0.55)($0.67)$5.00 million$4.94 millionViewListenView Earnings Details
12/17/2015Q3 2015($0.31)($5.25)$5.00 million$4.94 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Voyager Therapeutics (NASDAQ:VYGR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Voyager Therapeutics (NASDAQ VYGR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.60%
Institutional Ownership Percentage: 84.03%
Insider Trading History for Voyager Therapeutics (NASDAQ:VYGR)
Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ VYGR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2018Bernard RavinaInsiderSell2,451$18.38$45,049.38View SEC Filing  
3/23/2018Jane HendersonCFOSell11,200$20.52$229,824.0019,900View SEC Filing  
3/19/2018Jane HendersonCFOSell17,316$22.11$382,856.7615,416View SEC Filing  
3/16/2018Jane HendersonCFOSell15,416$22.15$341,464.4015,416View SEC Filing  
3/12/2018Bernard RavinaInsiderSell2,451$25.16$61,667.16View SEC Filing  
2/27/2018Dinah Ph.D. SahInsiderSell15,623$30.00$468,690.00140,872View SEC Filing  
2/12/2018Bernard RavinaInsiderSell2,451$18.24$44,706.244,902View SEC Filing  
1/10/2018Bernard RavinaInsiderSell3,630$16.40$59,532.007,353View SEC Filing  
12/11/2017Bernard RavinaInsiderSell5,490$13.63$74,828.7010,983View SEC Filing  
11/10/2017Bernard RavinaInsiderSell5,490$13.26$72,797.4016,473View SEC Filing  
10/10/2017Bernard RavinaInsiderSell10,980$20.33$223,223.40View SEC Filing  
9/11/2017Bernard RavinaInsiderSell16,470$12.87$211,968.90View SEC Filing  
9/5/2017Bernard RavinaInsiderSell5,490$10.00$54,900.0017,157View SEC Filing  
7/20/2017Bernard RavinaInsiderSell5,490$10.00$54,900.00View SEC Filing  
1/14/2016Steven M PaulCEOBuy10,000$14.07$140,700.00872,351View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Voyager Therapeutics (NASDAQ VYGR) News Headlines

Source:
DateHeadline
$3.00 Million in Sales Expected for Voyager Therapeutics (VYGR) This Quarter$3.00 Million in Sales Expected for Voyager Therapeutics (VYGR) This Quarter
www.americanbankingnews.com - May 22 at 1:54 AM
Voyager Therapeutics (VYGR) Presents At 21st Annual Meeting of the American Society of Gene and Cell Therapy - SlideshowVoyager Therapeutics (VYGR) Presents At 21st Annual Meeting of the American Society of Gene and Cell Therapy - Slideshow
seekingalpha.com - May 21 at 5:09 PM
-$0.62 Earnings Per Share Expected for Voyager Therapeutics (VYGR) This Quarter-$0.62 Earnings Per Share Expected for Voyager Therapeutics (VYGR) This Quarter
www.americanbankingnews.com - May 20 at 11:14 PM
Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual ...Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual ...
www.nasdaq.com - May 20 at 8:18 AM
Voyager: Running Into Key PresentationVoyager: Running Into Key Presentation
seekingalpha.com - May 15 at 5:48 PM
MRI Interventions Announces Strategic Agreement with Voyager Therapeutics for Neurosurgical Device Service, Supply and DevelopmentMRI Interventions Announces Strategic Agreement with Voyager Therapeutics for Neurosurgical Device Service, Supply and Development
finance.yahoo.com - May 15 at 5:48 PM
Voyager Therapeutics (VYGR) Receives Average Rating of "Buy" from AnalystsVoyager Therapeutics (VYGR) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 14 at 3:19 PM
Reader Inquiry: When Will Voyager Therapeutics Rebound?Reader Inquiry: When Will Voyager Therapeutics Rebound?
seekingalpha.com - May 14 at 8:29 AM
Voyager Therapeutics (VYGR) Stock Rating Reaffirmed by BTIG ResearchVoyager Therapeutics (VYGR) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - May 13 at 7:54 AM
An Ear To The Pharma: 8 Stocks To Watch (VYGR, BOLD, RXII, CYAD…)An Ear To The Pharma: 8 Stocks To Watch (VYGR, BOLD, RXII, CYAD…)
www.nasdaq.com - May 12 at 8:27 AM
Form 8-K Voyager Therapeutics, For: May 10Form 8-K Voyager Therapeutics, For: May 10
www.streetinsider.com - May 12 at 8:27 AM
BRIEF-Voyager Therapeutics Rpeorts Q1 GAAP Loss Per Share Of $0.63BRIEF-Voyager Therapeutics Rpeorts Q1 GAAP Loss Per Share Of $0.63
www.reuters.com - May 12 at 8:27 AM
Voyager Therapeutics (VYGR) Upgraded at WedbushVoyager Therapeutics (VYGR) Upgraded at Wedbush
www.americanbankingnews.com - May 11 at 5:49 PM
Voyager Therapeutics (VYGR) Releases Quarterly  Earnings ResultsVoyager Therapeutics (VYGR) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 4:54 PM
Canaccord Genuity Analysts Give Voyager Therapeutics (VYGR) a $35.00 Price TargetCanaccord Genuity Analysts Give Voyager Therapeutics (VYGR) a $35.00 Price Target
www.americanbankingnews.com - May 11 at 3:56 PM
Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate HighlightsVoyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights
finance.yahoo.com - May 10 at 8:26 AM
Voyager Therapeutics: 1Q Earnings SnapshotVoyager Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:26 AM
Voyager Therapeutics (VYGR) Expected to Announce Quarterly Sales of $4.00 MillionVoyager Therapeutics (VYGR) Expected to Announce Quarterly Sales of $4.00 Million
www.americanbankingnews.com - May 5 at 3:53 AM
Voyager Therapeutics (VYGR) Lifted to "Hold" at BidaskClubVoyager Therapeutics (VYGR) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - May 4 at 1:46 PM
-$0.58 EPS Expected for Voyager Therapeutics (VYGR) This Quarter-$0.58 EPS Expected for Voyager Therapeutics (VYGR) This Quarter
www.americanbankingnews.com - May 3 at 6:17 PM
Voyager Therapeutics (VYGR) Upgraded to "Buy" by ValuEngineVoyager Therapeutics (VYGR) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - May 2 at 2:02 PM
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy ...Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy ...
globenewswire.com - April 30 at 5:13 PM
Voyager Therapeutics (VYGR) Set to Announce Earnings on MondayVoyager Therapeutics (VYGR) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 30 at 9:38 AM
Report: Exploring Fundamental Drivers Behind WR Grace, NCI Building, Robert Half International, CACI International ...Report: Exploring Fundamental Drivers Behind WR Grace, NCI Building, Robert Half International, CACI International ...
globenewswire.com - April 27 at 8:31 AM
Form DEF 14A Voyager Therapeutics, For: Jun 14Form DEF 14A Voyager Therapeutics, For: Jun 14
www.streetinsider.com - April 27 at 8:31 AM
Report: Exploring Fundamental Drivers Behind W.R. Grace, NCI Building, Robert Half International, CACI International, PROS, and Voyager Therapeutics — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind W.R. Grace, NCI Building, Robert Half International, CACI International, PROS, and Voyager Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - April 27 at 8:30 AM
Stifel Nicolaus Reiterates "Buy" Rating for Voyager Therapeutics (VYGR)Stifel Nicolaus Reiterates "Buy" Rating for Voyager Therapeutics (VYGR)
www.americanbankingnews.com - April 20 at 4:16 PM
Voyager Therapeutics (VYGR) Downgraded by BidaskClubVoyager Therapeutics (VYGR) Downgraded by BidaskClub
www.americanbankingnews.com - April 19 at 10:42 AM
 Brokerages Expect Voyager Therapeutics (VYGR) Will Post Quarterly Sales of $3.17 Million Brokerages Expect Voyager Therapeutics (VYGR) Will Post Quarterly Sales of $3.17 Million
www.americanbankingnews.com - April 18 at 3:56 AM
Voyager Therapeutics (VYGR) Expected to Post Earnings of -$0.57 Per ShareVoyager Therapeutics (VYGR) Expected to Post Earnings of -$0.57 Per Share
www.americanbankingnews.com - April 16 at 11:18 AM
Voyager Therapeutics (VYGR) Downgraded by ValuEngineVoyager Therapeutics (VYGR) Downgraded by ValuEngine
www.americanbankingnews.com - April 15 at 10:59 AM
Voyager Therapeutics (VYGR) Insider Bernard Ravina Sells 2,451 SharesVoyager Therapeutics (VYGR) Insider Bernard Ravina Sells 2,451 Shares
www.americanbankingnews.com - April 12 at 4:33 PM
Voyager Therapeutics (VYGR) Upgraded to "Hold" by BidaskClubVoyager Therapeutics (VYGR) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 12 at 11:15 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and Zosano PharmaQuotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and Zosano Pharma
www.bizjournals.com - April 10 at 8:30 AM
Voyager Therapeutics (VYGR) Given a $35.00 Price Target by Canaccord Genuity AnalystsVoyager Therapeutics (VYGR) Given a $35.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 9 at 3:30 PM
Voyager Therapeutics (VYGR) Upgraded by ValuEngine to HoldVoyager Therapeutics (VYGR) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 2 at 10:22 PM
Voyager Therapeutics (VYGR) Stock Rating Lowered by ValuEngineVoyager Therapeutics (VYGR) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 1 at 2:04 PM
 Analysts Anticipate Voyager Therapeutics Inc (VYGR) Will Announce Quarterly Sales of $3.17 Million Analysts Anticipate Voyager Therapeutics Inc (VYGR) Will Announce Quarterly Sales of $3.17 Million
www.americanbankingnews.com - April 1 at 3:46 AM
Zacks: Analysts Anticipate Voyager Therapeutics Inc (VYGR) to Post -$0.57 EPSZacks: Analysts Anticipate Voyager Therapeutics Inc (VYGR) to Post -$0.57 EPS
www.americanbankingnews.com - March 30 at 1:18 PM
Jane Henderson Sells 11,200 Shares of Voyager Therapeutics Inc (VYGR) StockJane Henderson Sells 11,200 Shares of Voyager Therapeutics Inc (VYGR) Stock
www.americanbankingnews.com - March 26 at 4:10 PM
Voyager Therapeutics Inc (VYGR) Given Average Rating of "Buy" by BrokeragesVoyager Therapeutics Inc (VYGR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 25 at 3:36 PM
Voyager Therapeutics (VYGR) Downgraded by BidaskClub to "Sell"Voyager Therapeutics (VYGR) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 24 at 1:54 PM
Jane Henderson Sells 15,416 Shares of Voyager Therapeutics Inc (VYGR) StockJane Henderson Sells 15,416 Shares of Voyager Therapeutics Inc (VYGR) Stock
www.americanbankingnews.com - March 20 at 7:50 PM
Insider Selling: Voyager Therapeutics Inc (VYGR) CFO Sells 17,316 Shares of StockInsider Selling: Voyager Therapeutics Inc (VYGR) CFO Sells 17,316 Shares of Stock
www.americanbankingnews.com - March 20 at 7:50 PM
Voyager Therapeutics (VYGR) Downgraded by Zacks Investment Research to HoldVoyager Therapeutics (VYGR) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 20 at 1:50 PM
Voyager Therapeutics (VYGR) Upgraded at Zacks Investment ResearchVoyager Therapeutics (VYGR) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 16 at 3:06 PM
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:18 AM
Voyager Therapeutics (VYGR) CEO Steve Paul on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaVoyager Therapeutics' (VYGR) CEO Steve Paul on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 15 at 8:18 AM
Voyager Therapeutics (VYGR) Announces Quarterly  Earnings Results, Beats Estimates By $0.32 EPSVoyager Therapeutics (VYGR) Announces Quarterly Earnings Results, Beats Estimates By $0.32 EPS
www.americanbankingnews.com - March 15 at 7:56 AM
Voyager Therapeutics Inc (VYGR) Insider Sells $61,667.16 in StockVoyager Therapeutics Inc (VYGR) Insider Sells $61,667.16 in Stock
www.americanbankingnews.com - March 14 at 8:11 PM

SEC Filings

Voyager Therapeutics (NASDAQ:VYGR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Voyager Therapeutics (NASDAQ:VYGR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Voyager Therapeutics (NASDAQ VYGR) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.